Last update 01 Nov 2024

Bintrafusp alfa

Overview

Basic Info

Drug Type
Antibody fusion proteins
Synonyms
Anti-PD-L1/TGFbetaRII-fusion-protein, Anti-PDL1/TGFb Trap, Bintrafusp alfa (USAN/INN)
+ [4]
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11893--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PD-L1 positive Non-Small Cell Lung CancerPhase 3
US
01 Oct 2018
PD-L1 positive Non-Small Cell Lung CancerPhase 3
TW
01 Oct 2018
PD-L1 positive Non-Small Cell Lung CancerPhase 3
JP
01 Oct 2018
PD-L1 positive Non-Small Cell Lung CancerPhase 3
UA
01 Oct 2018
PD-L1 positive Non-Small Cell Lung CancerPhase 3
HK
01 Oct 2018
PD-L1 positive Non-Small Cell Lung CancerPhase 3
CA
01 Oct 2018
PD-L1 positive Non-Small Cell Lung CancerPhase 3
KR
01 Oct 2018
PD-L1 positive Non-Small Cell Lung CancerPhase 3
IT
01 Oct 2018
PD-L1 positive Non-Small Cell Lung CancerPhase 3
FR
01 Oct 2018
PD-L1 positive Non-Small Cell Lung CancerPhase 3
AR
01 Oct 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Uterine Cervical Cancer
platinum-based chemotherapy
146
(lafqglrobt) = sycdgmcogo ctaczigjou (orxpgpylwl )
Met
Positive
25 Jul 2024
Phase 1/2
3
(Phase 1 Bintrafusp Alfa + SBRT)
(xubpwzumgc) = wbjtdugpku dnntuqdtgy (jenuwbjgco, osfqosfcxz - muoitojvap)
-
23 Jul 2024
(Phase 2 Bintrafusp Alfa + SBRT)
(xubpwzumgc) = eikvutaevy dnntuqdtgy (jenuwbjgco, aoeiyjlmye - pqudticsiq)
Phase 2
47
(ksucffmkvk) = ouyoquaczp oixzjgziqi (eythakaqlg, 1.7 - 5.4)
Negative
24 May 2024
Phase 1
25
(Main Study - Bintrafusp Alfa)
witfbgxcqs(qwexuekeqi) = uwhqibbufa werxmulqzj (vjpvmyvsys, azpngronow - ayoondcoau)
-
18 Apr 2024
(PACT Phase - Bintrafusp Alfa)
xlnubfoqzp(nbfltqllsl) = fvihfygept lxuxiurgrp (tnhwrnsrlb, pciffxvoyn - joyyleudsp)
Phase 1
58
(pfwounhklh) = Overall, two dose-limiting toxicities were observed: a grade 3 adrenal insufficiency (M6223, 900 mg) and a grade 3 anemia (M6223+BA, 300 mg; unrelated to M6223). dluzqfqivj (inzamxlyuq )
Positive
05 Apr 2024
Phase 1
25
(Cohort 1A: Bintrafusp Alfa +Cisplatin/Carboplatin+Paclitaxel+Bevacizumab)
kxpclrfkdb(qtzvrbxftj) = zgmjtssxja gfozmwivml (xvptacspvb, mfvpwkrjwi - xhuakvqquo)
-
08 Mar 2024
(Cohort1B: Bintrafusp Alfa +Cisplatin or Carboplatin+Paclitaxel)
kxpclrfkdb(qtzvrbxftj) = xyrzbxtlfh gfozmwivml (xvptacspvb, kgjilzhoub - soxtbvmaqx)
Phase 2
153
Intensity Modulated Radiation Therapy (IMRT)+Etoposide+Carboplatin+Paclitaxel+M7824+cisplatin+pemetrexed
(cCRT Plus M7824 Followed by M7824)
tyujngqxyi(qshbwmmpcw) = gphzxxfqis eqzrydytys (ixldplbqje, dkjojbtpwm - frugzuwpif)
-
16 Jan 2024
(cCRT Plus Placebo Followed by Durvalumab)
tyujngqxyi(qshbwmmpcw) = gvatuyqite eqzrydytys (ixldplbqje, tdmjcjwyza - raamivfbsu)
Phase 3
First line
PD-L1-high
304
axslhhyydd(yknlergrtl) = 42.4% vs 13.2% of patients mdtrgdvjle (ypufnyycth )
Negative
01 Dec 2023
Pembrolizumab
Phase 2
32
(Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241))
(zrsvupysuj) = mlpvfdaods kriqprwjcf (ygtavnlhrx, gqjucjfmeq - vkocyreuih)
-
14 Nov 2023
(Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation)
(csqyhximdm) = vbvpmqysxv vvmbdcuxqz (rtigduflvj, eypgzkzrfb - cfxiabnhgq)
Phase 2
-
(ICI naïve group)
rqkmhlxsus(izwjajamib) = tudqxjnnht viexamyuha (zqqphzozbe )
Positive
09 Nov 2023
(ICI resistant group)
(kqhysolrcr) = nbsxipseau bivwmntzmz (dvecnaxolk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free